NASDAQ: LBPHLongboard Pharmaceuticals Inc Stock
$18.01+1.01 (+5.94%)
Updated Apr 18, 2024
LBPH Price
$18.01
Fair Value Price
$18.85
Market Cap
$648.67M
52 Week Low
$3.60
52 Week High
$28.15
P/E
-7.54x
P/B
15.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$54.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$51M
Beta
0.4
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LBPH Overview
Longboard Pharmaceuticals Incorporated is a biopharma company developing transformative medicines for neurological diseases. It lead product is LP352, in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Formerly known as Arena Neuroscience Inc., Longboard Pharmaceuticals was incorporated in 2020 and is headquartered in La Jolla, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LBPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LBPH ($18.01) is undervalued by 4.45% relative to our estimate of its Fair Value price of $18.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LBPH ($18.01) is not significantly undervalued (4.45%) relative to our estimate of its Fair Value price of $18.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LBPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LBPH due diligence checks available for Premium users.
Be the first to know about important LBPH news, forecast changes, insider trades & much more!
LBPH News
Valuation
LBPH fair value
Fair Value of LBPH stock based on Discounted Cash Flow (DCF)
Price
$18.01
Fair Value
$18.85
Undervalued by
4.45%
LBPH ($18.01) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LBPH ($18.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LBPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LBPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.54x
Industry
15.68x
Market
41.33x
LBPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.85x
Industry
5.76x
LBPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LBPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
LBPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$50.7M
Liabilities
$9.8M
Debt to equity
0.24
LBPH's short-term assets ($50.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LBPH's short-term assets ($50.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LBPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
-$1.6M
Financing
$3.0M
LBPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LBPH vs Biotech Stocks
Longboard Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.